Impact of CYP2C19 point-of-care testing on the clinical outcome in patients receiving personalized clopidogrel therapy: systemic review and meta-analysis.
Saved in:
| Title: | Impact of CYP2C19 point-of-care testing on the clinical outcome in patients receiving personalized clopidogrel therapy: systemic review and meta-analysis. |
|---|---|
| Authors: | Mohammed S; Pharmacy Department, Hamad Medical Corporation, Doha, Qatar.; Department of Pharmaceutical Life Sciences, Universiti Malaya, Kuala Lumpur, Malaysia., Ali Z; Pharmacy Department, Hamad Medical Corporation, Doha, Qatar., Mohammed N; Pharmacy Department, Hamad Medical Corporation, Doha, Qatar., El-Menyar A; Trauma and Vascular Research and Development at Hamad medical corporation, Doha, Qatar.; Clinical Medicine Department, Weill Cornell Medical College, Doha, Qatar., Al Suwaidi J; Department Hamad Medical Corporation, Cardiology and Cardiovascular Surgery, Doha, Qatar., Al-Hail M; Pharmacy Department, Hamad Medical Corporation, Doha, Qatar., Al-Muftah W; Qatar Genome Program, Qatar Precision Health Institute, Qatar Foundation, Doha, Qatar., Abdel-Latif R; Qatar Genome Program, Qatar Precision Health Institute, Qatar Foundation, Doha, Qatar.; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, Minia, Egypt., Sim MS; Department of Pharmaceutical Life Sciences, Universiti Malaya, Kuala Lumpur, Malaysia. |
| Source: | Frontiers in pharmacology [Front Pharmacol] 2025 Nov 21; Vol. 16, pp. 1621327. Date of Electronic Publication: 2025 Nov 21 (Print Publication: 2025). |
| Publication Type: | Journal Article; Systematic Review |
| Journal Info: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1663-9812 |
|---|---|
| DOI: | 10.3389/fphar.2025.1621327 |